Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Omega-3 in pediatric T1DM with diabetic nephropathy
NCT05980026Completed
- Sponsor
- Ain Shams University
- Start
- Jan 2022
- Primary completion
- Dec 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, double-blind trial of omega-3 fatty acid in diabetic nephropathy (DN) and atherosclerosis (2 arms), sponsored by Ain Shams University. Primary endpoint: Urinary Albumin-to-Creatinine Ratio at 6 months. Started Jan 2022; status: completed.
02
Drugs
omega-3 fatty acid
03
Conditions
diabetic nephropathy (DN)atherosclerosis
Beyond the preview
Go deeper on NCT05980026.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05980026.